Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Innocell™, an autologous whole-cell immunotherapy, has received FDA clearance for a first-in-human Phase 1 clinical study targeting patients with recurrent epithelial ovarian cancer. The therapy aims to delay disease progression following or alongside standard treatments such as chemotherapy, immunotherapy, radiotherapy, or surgery. Early-stage funding and grants have been secured to advance clinical development. No published efficacy data yet; focus is on safety and immunogenicity assessment.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Photon Medical.